Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optisulin versus Novomix30 for insulin-requiring gestational diabetes
ACTRN12626001094369Phase 4Not yet recruiting
- Sponsor
- Canberra Hospital Department of Endocrinology
- Start
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of insulin glargine and biphasic insulin aspart in gestational diabetes mellitus (GDM) and diabetes mellitus (DM) (2 arms), sponsored by Canberra Hospital Department of Endocrinology. Primary endpoint: Glycaemic control. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
insulin glarginebiphasic insulin aspart
03
Conditions
gestational diabetes mellitus (GDM)diabetes mellitus (DM)
Beyond the preview
Go deeper on ACTRN12626001094369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626001094369.